Clinical Trials Logo

Thrombocytopenia clinical trials

View clinical trials related to Thrombocytopenia.

Filter by:
  • Recruiting  
  • « Prev · Page 19

NCT ID: NCT01162941 Recruiting - Thrombocytopenia Clinical Trials

Efficacy of Helicobacter Pylori Eradication, Anti-D and Danazol Combination in Steroid Dependant or Refractory Immune Thrombocytopenia (ITP)

Start date: February 2010
Phase: Phase 2
Study type: Interventional

Proportion who would avoid splenectomy at 6 months of follow up

NCT ID: NCT01102790 Recruiting - Thrombosis Clinical Trials

Generation of Heparin-induced Thrombocytopenia (HIT)-Antibodies Without Prior Heparin Exposure

Start date: April 2010
Phase: N/A
Study type: Observational

The purpose of this study is to determine the HIT-antibody generation without prior heparin-exposure in patients undergoing orthopedic surgery.

NCT ID: NCT01101295 Recruiting - Clinical trials for Purpura, Thrombocytopenic, Idiopathic

The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.

ITP-RITUX
Start date: April 2010
Phase: N/A
Study type: Observational

The primary purpose of the study is to describe by a prospective observational study the serious adverse events occurring in patients treated off-label by rituximab for Immune Thrombocytopenia.

NCT ID: NCT00239733 Recruiting - HIV Infections Clinical Trials

Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection

Start date: March 2005
Phase: N/A
Study type: Interventional

Thrombocytopenia occurs when a person's blood has a decreased number of platelets, which are cells involved in blood clotting. This condition may lead to uncontrolled bleeding and can be fatal. Thrombocytopenia commonly occurs with hepatitis C virus (HCV) infection or as a result of standard HCV treatment. Anti-D is an antibody approved by the Food and Drug Administration (FDA) for the treatment of HIV-related thrombocytopenia. The purpose of this study is to determine the safety and effectiveness of intravenous anti-D for the treatment of thrombocytopenia in patients with HCV infection who are starting or already undergoing treatment with peginterferon alfa-2 and ribavirin. This study will recruit HCV patients both with and without HIV co-infection.